Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.
Pablo Tolosa(Research Institute Hospital 12 de Octubre), Eva Ciruelos(Hospital Universitario 12 De Octubre), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Cristina Hernándo(Hospital Clínico Universitario de Valencia), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Jordi Canes, Fernando Salvador(Solti), Javier David Benítez Fuentes(Universidad de Zaragoza), Ana María Roncero(Hospital Universitario Fundación Jiménez Díaz), María Cobos-Fernández(Hospital Universitario 12 De Octubre), Sonia Servitja(Hospital Del Mar), Aleix Prat(Hospital Clínic de Barcelona), María Fernández(Hospital Universitario Ramón y Cajal), María Moreno(Research Institute Hospital 12 de Octubre), Laura Lema(Hospital Universitario 12 De Octubre), L. Parrilla Rubio(Hospital Universitario 12 De Octubre), Manuel Alva Bianchi(Research Institute Hospital 12 de Octubre), Yolanda Ruano(Hospital Virgen de la Salud)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k